The Meningococcal Vaccine Market was worth US$ 3.2 billion in 2019 and is expected to reach US$ 7.77 billion by 2030 growing at a CAGR of 8.5% through 2030.
Meningococcal is the disease caused by a bacteria named Niesseria meningitides. This bacteria is also known as meningococcus. This causes a serious infection and forms thin lining that surrounds spinal cord and brain. This disease is often deadly and can cause severe illness. Fatality rate may be up to 50% if not treated in time.
Early detection and treatment is must to reduce the complications and save lives. This bacterium is spread via exchange of throat and respiratory secretions. This can be treated with antibiotics but quick diagnosis is needed. This disease can be prevented with meningococcal vaccine. There are two types of meningococcal vaccines available – meningococcal conjugate and serogroup B meningococcal vaccine.
Meningococcal meningitis cases are observed all over the world but the rate of this disease is higher in Sub-Saharan Africa region. Every year almost 30,000 cases are observed in this region. However, many global health organizations, private sector companies, academic research facilities/universities and public health bodies are working towards introducing initiatives to defeat the meningitis. World Health Organization (WHO) has also come up with an initiative of eradicating meningitis by 2030.
It has set out a road map to tackle the causes of bacterial meningitis. This road map identifies the key activities related to diagnosis and treatment, prevention and epidemic control, disease tracking and support for the people affected by the disease. Such kind of initiatives will support the growth of the market.
Although the cases of meningitis are declining over the past 20 years, in 2017, there were about 290,000 deaths and 5 million of new cases of meningitis all over the globe. According to WHO, between 2010 to 2017 about 157 districts of African countries experienced outbreaks of meningitis. Recommended vaccine programme for meningitis in some countries are still not available at a larger scale, thus putting the population in such countries at great risk.
North America has the larger share in the meningococcal vaccine market. This is attributed to regularized use of vaccine in this region. Many states have mandated the meningococcal vaccine for the school and college going students. Such kind of measures by the governments is propelling the growth meningococcal vaccine market in North America.
Meningococcal Vaccine Market Value Share Analysis, by Geography (2022)
The report titled “Meningococcal Vaccine Market- Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global meningococcal vaccine market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
The meningococcal vaccine market is segmented into type, age group and geography. Based on type the market is segmented into Conjugate, Polysaccharide, and others. Polysaccharide vaccine segment is further bifurcated into bivalent, trivalent, and tetravalent. On the basis of age group the market is sub-segmented into infants and adults. The infant segment have larger share in the market. Occurrence of meningitis is most common within the children below 5 years of age.
Based on geography, the global meningococcal vaccine market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Belgium, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, South Korea, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, the UAE, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global meningococcal vaccine market with a focus on all operating business segment and would identify and analyze the segment of the company focusing on meningococcal vaccine. Further, market share of prominent companies in the global meningococcal vaccine market would also be estimated.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focusing on the meningococcal vaccine companies. The global meningococcal vaccine market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products and innovations regarding meningococcal vaccine activities of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new innovations and patent filing information and geographic expansion in the global meningococcal vaccine market.
Key players operating in the global meningococcal vaccine market are GlaxoSmithKline, plc, Pfizer, Inc., Merck & Co., Inc., Sanofi Pasteur SA, Astellas Pharma Inc., CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Sciences Corporation, and Panacea Biotec, among others.
Companies are focusing on enhancing their distribution network in the countries where healthcare infrastructure is still not yet developed. Companies are looking forward to this as an untapped opportunity for their growth in the forecast period. Companies are still coming up with vaccines providing better prevention rate for meningitis. For instance in April 2020, a new vaccine, MenQuadfi a meningococcal conjugate vaccine produced by Sanfoi S.A. was approved by the FDA.
Market Segmentation:
By Type
By Age group
By Geography
The global meningococcal vaccine market is estimated to surpass US$ 7.77 Billion by 2030.
The global meningococcal vaccine market is estimated to expand at a CAGR of 8.5% through 2030.
The key activities related to diagnosis and treatment, prevention and epidemic control, disease tracking, and support for the people affected by the disease. Such kind of initiatives will support the growth of the market.
North America has the larger share in the meningococcal vaccine market. This is attributed to regularized use of vaccine in this region. Many states have mandated the meningococcal vaccine for the school and college going students. Such kind of measures by the governments is propelling the growth meningococcal vaccine market in North America.
The sample report for the meningococcal vaccine Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved